PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8751797-2	1996	Combination chemotherapy with cisplatin/etoposide (PE) or CAV (cyclophosphamide, adriamycin and vincristine) alternating with PE was established as standard regimens.	Cyclophosphamide	63-79	caveolin 2	Homo sapiens	58-61	
9626212-6	1998	CAV/PE consisted of cyclophosphamide 800 mg/m2; doxorubicin 50 mg/m2; and vincristine 1.4 mg/m2 on day 1, which alternated every 3 weeks with cisplatin 80 mg/m2 on day 1 and etoposide 100 mg/m2 on days 1 to 3.	Cyclophosphamide	20-36	caveolin 2	Homo sapiens	0-6	
9597676-3	1998	Either PE (platinum plus etoposide) or CAV (cyclophosphamide, Adriamycin, and vincristine) is a reasonable first-line therapy.	Cyclophosphamide	44-60	caveolin 2	Homo sapiens	39-42	
10422440-16	1999	Although 2 cycles of CAV/PE therapy with cyclophosphamide, doxorubicin, vincristine, CDDP, and VP-16 were performed following resection of the retroperitoneal tumor, he showed no response and decreased 24 months after surgery.	Cyclophosphamide	41-57	caveolin 2	Homo sapiens	21-27	
2201427-7	1990	The authors" patient was correctly diagnosed during life and received considerable benefit from cyclophosphamide, doxorubicin, and vincristine (CAV) therapy and survived for 26 months after diagnosis.	Cyclophosphamide	96-112	caveolin 2	Homo sapiens	144-147	
1656891-2	1991	He was treated three times with CAV (cyclophosphamide, doxorubicin, vincristine) therapy and a partial response was achieved.	Cyclophosphamide	37-53	caveolin 2	Homo sapiens	32-35	
1648333-1	1991	Both CAV (Cyclophosphamide, Doxorubicin, Vincristine) and PE (Cisplatin, Etoposide) are effective and non cross-resistant regimens in the treatment of SCLC.	Cyclophosphamide	10-26	caveolin 2	Homo sapiens	5-8	
2175049-0	1990	Treatment of small cell lung cancer with cyclophosphamide, adriamycin and vincristine (CAV) combination therapy: experience at University Hospital, Kuala Lumpur, Malaysia.	Cyclophosphamide	41-57	caveolin 2	Homo sapiens	87-90	
2153765-1	1990	The present randomized, prospective study was designed to assess whether alternating induction cyclophosphamide, doxorubicin, vincristine-altretamine (hexamethylmelamine), etoposide, and methotrexate (CAV-HEM) chemotherapy is better than standard chemotherapy (CAV) in improving response, survival, and remission time in 577 evaluable patients having extensive-disease small-cell lung cancer (SCLC).	Cyclophosphamide	95-111	caveolin 2	Homo sapiens	201-204	
2154857-2	1990	Twenty-five patients had prior exposure to cisplatin plus etoposide, and 14 of the 26 patients (54%) had prior therapy with CAV (cyclophosphamide, doxorubicin, and vincristine).	Cyclophosphamide	129-145	caveolin 2	Homo sapiens	124-127	
2820571-2	1987	The effectiveness of both cyclophosphamide, doxorubicin, and vincristine (CAV) and etoposide and cisplatin (VPP) in previously untreated patients with small cell lung cancer has been well-documented.	Cyclophosphamide	26-42	caveolin 2	Homo sapiens	74-77	
2839116-6	1988	A current study comparing the standard chemotherapy with cyclophosphamide, adriamycin and vincristine (CAV) to alternating CAV with etoposide (E) and cisplatin (P) has suggested an advantage for alternating chemotherapy, with a statistically superior response rate and survival.	Cyclophosphamide	57-73	caveolin 2	Homo sapiens	103-106	
3020704-5	1986	In addition, combination chemotherapy studies using etoposide have yielded toxicity equivalent to IV administered programs such as CAV (cyclophosphamide, doxorubicin, vincristine).	Cyclophosphamide	136-152	caveolin 2	Homo sapiens	131-134	
16532434-2	2006	The authors report on their results from a regimen of ifosfamide, carboplatin, and etoposide (ICE) with cyclophosphamide, doxorubicin, and vincristine (CAV) dose intensification in patients with high-risk ESFT.	Cyclophosphamide	104-120	caveolin 2	Homo sapiens	152-155	
1056807-2	1975	Cyclophosphamide, cytosine arabinoside and vincristine (CAV) therapy resulted in complete remission in 23 of 50 previously untreated patients with AML and in 3 of the 11 patients with CML.	Cyclophosphamide	0-16	caveolin 2	Homo sapiens	56-59